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immune function, hypogonadotropic hypogonadism, re-
duced growth hormone secretion, hypothalamic hypothy-
roidism or reduced adult height. We provide a detailed de-
scription of the phenotype of 2 affected girls to add to this 
knowledge.  Methods: Whole-exome sequencing and target-
ed sequencing were used to detect the  LEPR mutations. RNA 
analysis was performed to assess the effect of splice-site mu-
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 Abstract 
 Background: Recessive mutations in the leptin receptor 
 (LEPR) are a rare cause of hyperphagia and severe early-onset 
obesity. To date, the phenotype has only been described 
in 25 obese children, some of whom also had altered
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 Established Facts 
 • Leptin receptor (LEPR) deficiency causes hyperphagia and severe early-onset obesity. 
 • Other features such as hypogonadotropic hypogonadism, reduced growth hormone secretion, hypo-
thalamic hypothyroidism and altered immune function are more variable. 
 • Leptin has been implicated as an important factor in bone metabolism. 
 Novel Insights 
 • Two girls with LEPR deficiency have a high bone mineral density, as assessed by dual-energy X-ray 
absorptiometry, which may be directly or indirectly related to leptin resistance. 
 • Bone age is remarkably advanced in the prepubertal girl, suggesting leptin resistance might also favor 
bone maturation. 
 H.A.D.-v.d.W. deceased on February 13, 2014. 
Th is article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-
tribution of modifi ed material requires written permission. Do
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tations.  Results: In 2 unrelated girls with severe obesity, three 
novel  LEPR mutations were detected. Longitudinal growth 
data show normal childhood growth, and in the older girl, a 
normal adult height despite hypogonadotropic hypogonad-
ism and the lack of an obvious pubertal growth spurt. Bone 
age is remarkably advanced in the younger (prepubertal) girl, 
and bone mineral density (BMD) is high in both girls, which 
might be directly or indirectly related to leptin resistance. 
 Conclusion: The spectrum of clinical features of LEPR defi-
ciency may be expanded with increased BMD. Future obser-
vations in LEPR-deficient subjects should help further unrav-
el the role of leptin in human bone biology. 
 © 2016 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Leptin is a key regulator of energy homeostasis. It is 
produced by adipocytes and signals information on the 
amount of energy stored as body fat to the brain. It binds 
to the leptin receptor (LEPR), which is expressed in the 
hypothalamus, where it influences satiety and plays an 
important role in the regulation of the hypothalamus-pi-
tuitary-gonadal axis. LEPR is also expressed in other 
brain regions such as the cortex, midbrain and hindbrain, 
where its role is not completely clear yet  [1] .
 Recessive mutations of  LEPR are a rare cause of hyper-
phagia and severe early-onset obesity  [2, 3] . To date, the 
phenotype has only been described in 25 children  [2–10] . 
All were severely obese; in some subjects, additional fea-
tures were reported, e.g. (clinical features of) altered im-
mune function/T-cell numbers  [3, 4, 7, 10] , hypogonado-
tropic hypogonadism  [3, 6, 8] , reduced growth hormone 
(GH) secretion  [2, 8] , hypothalamic hypothyroidism  [2, 
8] , and reduced adult height  [3] . No data are available on 
bone health in these patients, although LEPR is known to 
be involved in bone metabolism  [11, 12] .
 Here, we describe the clinical and laboratory features 
of 2 girls with LEPR deficiency to further delineate the 
phenotype in childhood and adolescence. We show nor-
mal childhood growth, normal adult height in the oldest 
girl, and high bone mineral density (BMD) in both girls.
 Case Reports 
 Patient 1 
 The girl was born at full term with a birth weight of 3,560 g. She 
suffered from pyelonephritis at the age of 4 months but experi-
enced no other serious infections. She showed normal psychomo-
tor development. From infancy, her appetite seemed insatiable and 
she gained weight quickly ( fig. 1 a–d). Despite a restricted diet and 
exercise program, she remained severely obese. Weight at the age 
of 9.0 years was 75.7 kg (+3.4 SDS weight-for-height), BMI 33.1 
(+4.6 SDS), with a lean body mass of 40.5 kg, a fat mass of 32.5 kg 
and a fat percentage of 43.7% measured by dual-energy X-ray ab-
sorptiometry with the Hologic Discovery A system (Hologic Inc., 
Waltham, Mass., USA). Growth accelerated between the age of 1 
and 4 years, followed by stable growth along +2.3 SDS at the upper 
border of the target height (TH) range (+0.8 SDS ± 1.6) but close 
to maternal height SDS (185.2 cm, +2.4 SDS). Pubic hair first ap-
peared at the age of 8.5 years; however, breast development had not 
started by the age of 9 years.
 The family is of Dutch origin, with all grandparents being 
Dutch. The patient’s father is obese (height 181 cm, weight 123 kg, 
BMI 37.5 at the age of 49 years) but had normal weight as a child. 
Her mother (height 186 cm, weight 76 kg, BMI 22.0 at the age of 
38 years), sister (height 152 cm, weight 40 kg, BMI –0.1 SDS at the 
age of 12 years) and brother (height 122 cm, weight 25 kg, BMI 
+1.2 SDS at the age of 6.5 years) are not overweight.
 Laboratory investigations at the age of 9.5 years showed a se-
rum leptin level of 67.2 μg/l, which is above the reference range 
based on individuals with a normal BMI (3.7–11.1 μg/l) but within 
the range found in obese children (52.5 ± 20.2 μg/l in 151 children 
at the age of 12.3 ± 2.4 years and with a BMI z-score +2.7)  [13] . 
Thyroid function, plasma insulin-like growth factor 1 (IGF1; +1.1 
SDS), fasting glucose, liver enzymes, total and LDL cholesterol 
were normal, and serum LH, estradiol, testosterone, FSH and an-
drostenedione were consistent with prepubertal status. Fasting in-
sulin was mildly elevated (23 mU/l), triglycerides were high (1.54 
mmol/l, >95th centile) and HDL cholesterol was low (0.79 mmol/l, 
<5th centile for age). 
 Bone age (BA) according to Greulich and Pyle  [14] , however, 
was remarkably advanced [12 years at a calendar age (CA) of 8.6 
years], and dual-energy X-ray absorptiometry showed BMD z-
scores of +2.7, +3.1 and +3.4 at the lumbar spine (LS), neck area of 
the left hip and of the right hip, respectively (reference data for 
BMD are from NHANES). LS bone mineral apparent density 
(BMAD) z-scores were +1.9 at the age of 8.6 years and +2.3 at the 
age of 6.7 years, calculated as described by Ward et al.  [15] .
 Patient 2 
 The girl was born at term with a birth weight of 3,600 g. Her 
development was normal, although walking was somewhat de-
layed. Parents reported a normal appetite and food intake through-
out childhood. However, her weight increased dramatically after 
the age of 1 year, and various diets and exercise programs had no 
effect. She had no health complaints and grew along her TH SDS 
( fig. 1 e, f). Breast development started around the age of 11 years, 
but menarche had not yet occurred at the age of 15.2 years (mater-
nal menarcheal age was 14 years). Height was 170.3 cm (+0.5 SDS, 
close to the TH of 168.4 cm), weight was 110.3 kg, BMI was 38 
(+3.8 SDS), and Tanner stage was B5P5A3. Pubic hair was Tanner 
5, but remarkably sparse.
 The family is of Dutch origin, with all grandparents being 
Dutch. Her father is overweight (height 180 cm, weight 87 kg, BMI 
26.9). Her mother (height 168 cm, weight 57 kg, BMI 20.2) and 
sister (height 136 cm, weight 32 kg, BMI +0.8 SDS at the age of 9 
years) are not overweight.
 Fasting glucose was normal with elevated insulin (36.7 mU/l), 
and an oral glucose tolerance test revealed impaired glucose toler-
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 Fig. 1.  a ,  b Photographs of patient 1 at the age of 6 years and 8 
months, showing severe obesity but no dysmorphic features.  c –
 f Growth charts.  c Height for age of patient 1, showing early growth 
acceleration followed by steady growth at the upper border of the 
TH range. The shaded area represents –2 to +2 SDS. TH is indi-
cated by ‘TH’ on the right hand side of the graph. Note the ad-
vanced BA, which is indicated by a dot connected by a horizontal 
line to the height data point.  d Weight for height of patient 1, show-
ing early-onset obesity.  e Height for age of patient 2, showing nor-
mal growth but no pubertal growth spurt.  f Weight for height of 
patient 2. 
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ance (2 h glucose 7.8 mmol/l). Serum leptin was 79.4 μg/l, which is 
above the reference range based on individuals with a normal BMI 
(3.7–11.1 μg/l) but comparable to levels found in severely obese 
individuals with normal  LEPR  [3] . Thyroid function, IGF1 (+0.5 
SDS), androstenedione and cortisol were normal. DHEA-S was 
low (0.89 μmol/l, normal 1–12). Baseline gonadotropins (LH 0.3 
mU/l, FSH 1.1 mU/l) and estradiol (37 pmol/l) were low, as well as 
the responses to a gonadotropin-releasing hormone (GnRH) test 
(LH and FSH 5.1 and 2.8 U/l, respectively), confirming hypogo-
nadotropic hypogonadism. At the age of 15 years, estradiol supple-
mentation was started. In the following 2 years, the patient grew
4 cm. BA was 13.5 years at a CA of 15.2 years  [14] . BMD z-scores 
were +1.3 and +2.0 at the LS and proximal left femur, and the LS 
BMAD z-score was +1.7  [15] .
 Methods 
 Genomic DNA was isolated from peripheral blood samples us-
ing the AUTOPURE LS Instrument (Gentra Systems, Minneapo-
lis, Minn., United States). Cytogenetic microarray analysis was 
performed using the Affymetrix CytoScan HD Array according to 
the manufacturer’s procedures. Copy number was assessed in the 
proband using ChAS software (Chromosome Analysis Suite; Af-
fymetrix, El Segundo, Calif., USA). Sanger sequencing of the com-
plete coding region including intron-exon boundaries was per-
formed using standard procedures (primer sequences available 
upon request). Exomes were captured by the NimbleGen SeqCap 
EZ V2 kit, followed by Illumina paired-end sequencing (2 × 100 
bp) with at least ×40 mean coverage. Whole-exome sequencing 
data were generated in the Human Genotyping Facility of the Ge-
netic Laboratory at the Department of Internal Medicine, Erasmus 
Medical Centre. Downstream analysis was performed with an in-
house pipeline  [16] . 
 Two peripheral blood cultures for each patient were set up for 
RNA analysis: one with and one without cycloheximide. RNA was 
isolated with the RNA-Bee (Bio-connect B.V., Huissen, The Neth-
erlands) method using NucleoSpin ® RNA II columns (Nu-
cleoSpin ® RNA II kit; Macherey-Nagel, Düren, Germany) accord-
ing to the manufacturer’s instructions. RT-PCR was performed 
with home-made primers (sequences available upon request), and 
Sanger sequencing was performed according to standard proce-
dures. The investigations in patient 1 were approved by the Medi-
cal Ethics Committee of the Leiden University Medical Hospital 
(P06.118), and the investigations in patient 2 were performed in 
the context of routine patient care. Informed consent was obtained 
from patients and parents.
 Results 
 In both patients, a monogenic cause of obesity was 
suspected because of severe early-onset obesity and lean 
family members. In patient 1, whole-exome sequencing 
was performed in the index, her parents and two sib-
lings. This revealed two novel  LEPR mutations in the 
index, a splice-site mutation c.1753–1dupG in intron 13 
and a missense mutation c.2168C>T p.Ser723Phe in 
exon 16. RNA analysis of the splice-site mutation r.1753–
1dupG showed that the splice-acceptor site shifts one 
nucleotide, causing the retention of an extra nucleotide 
in the mRNA and a frameshift with a premature stop 
codon p.Met585Aspfs * 2 ( fig. 2 ,  3 ). The substituted ser-
ine (p.Ser723Phe) is a highly conserved amino acid 
(conserved in 11 species) in the fibronectin type III do-
main. The mutation of this residue is predicted to be 
pathogenic by in silico prediction programs [SIFT: del-
eterious (score 0.0; median 3.38); PolyPhen: probably 
damaging; HumDiv: score 1.000; HumVar: score 0.999; 
Mutation Taster: disease causing a p value of 1.0]. The 
mother and sister carry the missense mutation, the 
brother has two wild-type alleles and the father carries 
the splice mutation. 
 A CytoScan in patient 2 showed a paternal interstitial 
duplication on chromosome 2 containing part of the 
 CNTNAP5 gene. Since her father was not severely obese, 
we concluded that the duplication was likely to be a rare 
polymorphism without clinical significance. Of interest 
was a region of homozygosity of 7.5 Mb on chromosome 
1 containing the  LEPR gene. Sanger sequencing con-
firmed the presence of a novel homozygous  LEPR muta-
tion, c.1604–8A>G, in intron 12. mRNA analysis showed 
two transcripts, one with retention of 7 nucleotides from 
intron 12 (r.1604–7_1604–1insTTTCTAG) and one 
missing exon 13 (r.1604_1752del;  fig.  2 ,  3 ). Both tran-
scripts result in a frameshift and premature stop codon 
(p.Lys597Serfs * 34 and p.Val596Aspfs * 3, respectively). 
The transcripts were present at very low levels, indicating 
rapid degradation.
 Once the  LEPR mutations had been identified, labora-
tory tests were performed to exclude an immune defi-
ciency. Lymphocyte subsets and T-cell proliferative re-
sponses to stimulation by aCD3, IL-2/CD28, PHA/IL2 
and tetanus toxoid were normal in both patients.
 Discussion 
 These 2 girls, together carrying three novel  LEPR mu-
tations, show the classical phenotype of LEPR deficiency 
with severe obesity from the first year of life  [3] . Patient 2 
denies hyperphagia, which has been reported in all other 
patients, but appetite was not objectively assessed. 
 In patient 1, pathogenicity of the amino acid substitu-
tion variant was not confirmed by functional studies, but 
based on the evolutionary conservation of this amino acid 
and the in silico prediction, we consider it highly likely 
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that this was a pathogenic mutation. RNA analysis showed 
that the splice-site mutation gave rise to a frameshift and 
premature stop codon. RNA analysis in patient 2 showed 
that the homozygous mutation, due to alternative splic-
ing, resulted in two transcripts that were formed from the 
same pre-mRNA. Both these mRNA molecules resulted 
in a frameshift and premature stop codon.
 The father of patient 1 is obese (BMI 37.5), as has pre-
viously been reported in some heterozygous carriers  [7] 
but not in others  [3] . He had normal weight as a child and 
 Fig. 2. Sanger sequencing results of the RNA of patient 1 (upper 
panel) and patient 2 (lower panel) compared to the wild-type se-
quence. Both patients show two transcripts. In patient 1, the wild 
type and mutant r.1753–1dupG transcript are visible, while in pa-
tient 2, the mutant transcript r.1604–7_1604–1insTTTCTAG (ex-
ons 12–13) and the mutant transcript with the skip of exon 13 
(r.1604_1752del; exons 12–14) are seen. Exon numbers are indi-
cated below the sequences. The vertical box indicates the first nu-
cleotide of the exon. F = forward; R = reverse. 
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only gained weight after adolescence. The fact that obe-
sity did not develop until adulthood may be interpreted 
as evidence against a causal role of the obviously congen-
ital  LEPR  mutation. However, the development of obe-
sity during adulthood was also observed by others in het-
erozygous subjects  [8] . The heterozygous mother and sis-
ter have normal weight.
 Prepubertal LEPR-deficient children were reported to 
be tall  [5] , but to the same extent as equally obese subjects 
without  LEPR mutations  [3] . However, two LEPR-defi-
cient sisters with poor growth and low GH secretion have 
also been described  [2] . A lack of pubertal growth spurt 
with reduced adult height was described by some  [3] , al-
though others reported normal adult height  [6] . Our pa-
tient 1 showed growth acceleration during the first 4 
years, followed by steady growth within the TH range, 
and patient 2 did not show an evident pubertal growth 
spurt but continued to grow along her TH SDS to achieve 
a normal adult height.
 Patient 1 had a remarkably advanced BA (BA/CA ratio 
1.4) despite prepubertal levels of estrogens and andro-
gens. BA was more advanced than usually seen in chil-
dren of similar BMI SDS and age (BA/CA ratio 1.2 ± 0.3) 
 [17] . A very advanced BA was previously reported in pre-
pubertal children with leptin deficiency  [11, 18–20] , but 
a 13.8-year-old leptin-deficient girl with arrested puberty 
and low estradiol had a slightly retarded BA of 13.3 years 
 [21] . Several studies also reported an advanced BA in 
a
b
c
 Fig. 3.  a Schematic representation of the wild-type and mutant 
transcripts in patient 1 and patient 2. Numbered boxes represent 
exons; fragment sizes are indicated. Premature stop codons are 
indicated with an asterisk. The wild-type product of exons 12–14 
is 573 bp. The splice-site mutation in patient 1 gives a fragment of 
574 bp. The amino acid substitution mutation is located in exon 
16, i.e. outside this fragment. Patient 2 has two different transcripts 
resulting from one mutation: one with a skip of exon 13 (411 bp) 
and one with a 7-bp insertion (580 bp).  b ,  c RT-PCR products of 
patient 1 on agarose gel ( b ) and of patient 2 on Labchip ( c ). NC 
indicates the normal control, P the patient; – without and + with 
cycloheximide (inhibits nonsense-mediated decay); –RT without 
and +RT with reverse transcriptase. b indicates blank (no RNA). 
Fragment sizes are indicated on the right hand side. Fragments of 
573, 574 and 580 bp cannot be discriminated with these tech-
niques, but the Labchip 411-bp fragment that does not contain 
exon 13 is clearly visible. 
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some, but not all, patients with lipodystrophy, who have 
low or undetectable leptin levels  [11, 22] . The fact that 
advanced BA is reported in prepubertal children with ab-
sent/reduced leptin levels or  LEPR mutations suggests 
that absent or decreased leptin signaling favors bone mat-
uration. Elfeteriou et al.  [11]  interpreted the advanced BA 
as an indirect sign of premature bone formation caused 
by the absence of leptin as an anti-osteogenic factor. In-
terestingly, both our patients had relatively high BMD 
and BMAD levels. In the first patient, tall stature and ad-
vanced BA could partially explain the high BMD. How-
ever, the second patient had an average height for age and 
a retarded BA, and since she was hypogonadal, her BMD 
was expected to be low. Increased BMD may be related to 
obesity  [23, 24] , although other studies failed to confirm 
these findings  [17] . This raises the question whether 
leptin itself might directly affect bone metabolism, which 
is possible as  LEPR is expressed in (adult) osteoblasts and 
chondrocytes  [25] .
 Data from animal models provide conflicting data on 
the effect of leptin on bone. In mouse models, defects in 
leptin signaling were found to result in an increased bone 
mass by some  [26, 27] . In contrast, others found a re-
duced bone mass in leptin-deficient mice  [28, 29] . Differ-
ent effects of leptin administration on bone have been 
observed, possibly due to different routes of administra-
tion, with intracerebroventricular infusion being associ-
ated with bone loss  [27] and peripheral administration 
with increased bone formation  [30] . Age may also be a 
determinant of the effect of leptin, as a leptin antagonist 
was found to have a positive effect on bone formation in 
young mice but no effect in older mice  [31] .
 The role of leptin in human bone metabolism also re-
mains elusive. In obese subjects leptin levels are positive-
ly correlated to BMD z-scores  [23] , although this associa-
tion may not be independent but mediated through fat 
mass  [32] . Unravelling the link between leptin and bone 
in obesity is complicated by the finding of a state of leptin 
resistance in obesity. This was first observed in animal 
models and is evident from the fact that elevated leptin 
levels do not result in a return to normal weight  [33] . 
 In women with hypoleptinemia due to strenuous ex-
ercise treatment with recombinant methionyl, human 
leptin (metreleptin) increased the bone mineral content 
(BMC) of the LS but not at other sites  [34] . However, the 
increased BMC may be mediated by the increase in estra-
diol levels and decrease in cortisol levels observed during 
metreleptin treatment  [34] . A study of three leptin-defi-
cient adults reported normal BMD at the LS in 2 females 
and low BMD (z-score –2.36) in 1 male, who also suffered 
from hypogonadism  [35] . Farooqi et al.  [20] described 
normal BMD in 3 leptin-deficient children, and BMD in 
these children continued to develop as expected for age 
and gender during metreleptin treatment, although ac-
tual z-scores were not provided. On the other hand, indi-
viduals, including children, with hypoleptinemia due to 
lipodystrophy were found to have an increased BMC SDS 
of the total body less head, also when adjusted for height, 
and an increased BMD at the LS and hip  [22] . Treatment 
with recombinant leptin had no effect on BMD in indi-
viduals with lipodystrophy  [22, 36] . 
 These findings led us to hypothesize that in humans, 
decreased or absent leptin signaling favors an increase in 
bone mass. As seen within a group of individuals with li-
podystrophy, BMC may not be outside the normal range 
in all affected subjects despite a clearly higher BMC of the 
group as a whole  [22] . This might also explain why the 3 
leptin-deficient children had a normal rather than an el-
evated BMD, although this remains speculative as no z-
scores were provided so that it is unclear whether these 
children even had a BMD >0 SDS. In older individuals, 
other factors such as hypogonadism may explain a low 
BMD despite reduced or lost leptin signaling.
 Leptin signaling has been suggested to affect bone me-
tabolism directly through effects on osteoblasts and indi-
rectly through altered activity of the (sympathetic) ner-
vous system, GH, IGF1, parathyroid and thyroid hor-
mones, cortisol and estrogen  [12] . The finding that obese 
subjects with a mutation in  MC4R , which acts down-
stream of the LEPR, also have a high BMD  [37] suggests 
that leptin may act on proopiomelanocortin-producing 
neurons and then through the melanocortin 4 receptor 
on paraventricular neurons to influence bone metabo-
lism. The pathway further downstream is not clear. In the 
patients we describe herein, no abnormalities in the se-
rum levels of IGF1, PTH or thyroid function were ob-
served, although this does not exclude a role of these hor-
mones in the bone phenotype.
 Patient 2 had hypogonadotropic hypogonadism, 
which has previously been reported in several LEPR-de-
ficient subjects  [2, 3, 6, 8] . In leptin-deficient patients with 
hypogonadotropic hypogonadism, a normal response to 
GnRH has been described by some, which was seen as 
evidence for the hypothalamic origin of hypogonadism 
 [35] , but others found a low response to GnRH as we did 
 [2] .  LEPR is expressed by mouse gonadotropes and may 
be important in the regulation of GnRH binding  [38] . 
This suggests that hypogonadism in LEPR deficiency may 
be due to a defect both at the hypothalamic and at the pi-
tuitary level. However, hypogonadism may change over 
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time, as a low response to GnRH was reported in a 
16-year-old LEPR-deficient boy who had a normal re-
sponse at the age of 19 years  [6] . Another case with a low 
response to GnRH as a teenager later had spontaneous 
pubertal development and a natural pregnancy  [39] . 
 In previous studies, hyperinsulinemia or insulin resis-
tance was observed in 10/10 and 5/9 LEPR-deficient sub-
jects studied; 2 middle-aged subjects and 1 20-year-old 
had type 2 diabetes mellitus  [3] . Patient 2 from the cur-
rent study already has impaired glucose tolerance, sug-
gesting that progression of hyperinsulinemia to type 2 
diabetes mellitus may occur at a young age. Neither of the 
2 patients had immune defects in contrast to 9 previously 
studied LEPR-deficient children  [3, 4, 7] . 
 In conclusion, we describe 2 girls with severe obesi-
ty caused by novel  LEPR mutations. The longitudinal 
growth data show normal childhood growth; the older 
girl reached normal adult height despite hypogonado-
tropic hypogonadism and the lack of an obvious pubertal 
growth spurt. BA is remarkably advanced in the younger 
girl, and BMD is high in both girls, which might be re-
lated to leptin resistance. With the description of more 
patients with LEPR deficiency, it becomes obvious that 
the phenotype is variable, with early-onset obesity as a 
common feature and hypogonadotropic hypogonadism 
and immune deficiency for example as more variable fea-
tures. More data on bone development in LEPR-deficient 
subjects should help further unravel the role of leptin in 
human bone.
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